ArticleNPJ Parkinson's disease2024

Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.

Diana L Price et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.